Skip to main content

Table 4 Adverse events in 26 systemic sclerosis patients treated with imatinib

From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Adverse event

Number of patients

%

Lower limb edema

5

19.2

Cough

5

19.2

Infections

5

19.2

Urticaria/rash

4

15.3

Arthritis

2

7.6

Transient creatine kinase elevation

1

3.8

Diarrhea

1

3.8

Thrombophlebitis

1

3.8

Others

4

15.3